Abstract | BACKGROUND: METHODS: Randomized controlled trials were evaluated. Outcome measures were pain scores and demand for supplementary analgesia 0-24 h after surgery. RESULTS: Thirty-three studies were included in which four COX-2 inhibitors, rofecoxib 50 mg, celecoxib 200 and 400 mg, parecoxib 20, 40 and 80 mg, and valdecoxib 10, 20, 40, 80 mg were evaluated. Ten of these studies included 18 comparisons of rofecoxib, celecoxib, or parecoxib with NSAIDs. Rofecoxib 50 mg and parecoxib 40 mg provided analgesic efficacy comparable to that of the NSAIDs in the comparisons, and with a longer duration of action after dental surgery but possibly not after major procedures. Celecoxib 200 mg and parecoxib 20 mg provided less effective pain relief. Four studies included five comparisons of rofecoxib 50 mg with celecoxib 200 and 400 mg. Rofecoxib 50 mg provided superior analgesic effect compared with celecoxib 200 mg. Data on celecoxib 400 mg were too sparse for firm conclusions. Thirty-three studies included 62 comparisons of the four COX-2 inhibitors with placebo and the COX-2 inhibitors significantly decreased post-operative pain. CONCLUSION:
|
Authors | J Rømsing, S Møiniche |
Journal | Acta anaesthesiologica Scandinavica
(Acta Anaesthesiol Scand)
Vol. 48
Issue 5
Pg. 525-46
(May 2004)
ISSN: 0001-5172 [Print] England |
PMID | 15101847
(Publication Type: Comparative Study, Journal Article, Review, Systematic Review)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Cyclooxygenase Inhibitors
- Isoxazoles
- Lactones
- Pyrazoles
- Sulfonamides
- Sulfones
- rofecoxib
- valdecoxib
- parecoxib
- Celecoxib
|
Topics |
- Anti-Inflammatory Agents, Non-Steroidal
(therapeutic use)
- Celecoxib
- Cyclooxygenase Inhibitors
(therapeutic use)
- Humans
- Isoxazoles
(therapeutic use)
- Lactones
(therapeutic use)
- Pain Measurement
- Pain, Postoperative
(prevention & control)
- Pyrazoles
- Randomized Controlled Trials as Topic
- Sulfonamides
(therapeutic use)
- Sulfones
- Treatment Outcome
|